2013 RSC/SCI. Fragment Based Drug Discovery of a Potent Dual Antagonist of XIAP and cIAP1

2013 RSC/SCI. Fragment Based Drug Discovery of a Potent Dual Antagonist of XIAP and cIAP1

2013 ASH: Phase I/II Open-label study of AT7519 alone and in combo with bortezomib in pts with MM

2013 ASH: Phase I/II Open-label study of AT7519 alone and in combo with bortezomib in pts with MM

2013 ASH: DNA Demethylation Activity over time and safety regimens of SGI-110 in r/r MDS and AML pts

2013 ASH: DNA Demethylation Activity over time and safety regimens of SGI-110 in r/r MDS and AML pts

2013 Cell Symposia: Cancer Epigenomics. Anti-tumour Activity of SGI-110, a Novel Hypomethylating

2013 Cell Symposia: Cancer Epigenomics. Anti-tumour Activity of SGI-110, a Novel Hypomethylating

2013 ECCO: Study of correlation baseline biomarkers and DNA demethylation to clin response of SGI-11

2013 ECCO: Study of correlation baseline biomarkers and DNA demethylation to clin response of SGI-11

2013 AACR: SGI-110 induces Cancer Germline (CG) antigen expression in Acute Myeloid Leukemia cells

2013 AACR: SGI-110 induces Cancer Germline (CG) antigen expression in Acute Myeloid Leukemia cells

2013 EORTC: Epigenetic priming with SGI-110 improved antitumor activity of CTLA-4 blockade

2013 EORTC: Epigenetic priming with SGI-110 improved antitumor activity of CTLA-4 blockade

2013 EHA: Outcomes of intermediate or high risk MDS patients post azacitidine and or decitabine

2013 EHA: Outcomes of intermediate or high risk MDS patients post azacitidine and or decitabine

2013 AACR: Novel Small Molecule DNA Methylation Inhibitor SGI-110 as Ovarian Cancer Chemosensitizer

2013 AACR: Novel Small Molecule DNA Methylation Inhibitor SGI-110 as Ovarian Cancer Chemosensitizer

2013 AACR: In vivo immunomodulatory activity of SGI-110, a second generation hypomethylating agent

2013 AACR: In vivo immunomodulatory activity of SGI-110, a second generation hypomethylating agent